KENILWORTH, N.J., May 30 NJ-Schering-Plough
KENILWORTH, N.J., May 30 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) announced today that about 80 posters, poster
discussions, and oral presentations from about 60 clinical studies relating to
its growing oncology franchise will be presented at the upcoming 44th Annual
Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30
- June 3. Data will be presented on TEMODAR(R) (temozolomide) Capsules,
CAELYX(R) (pegylated liposomal doxorubicin hydrochloride), INTRON(R) A
(Interferon alfa-2b, recombinant) for Injection and peginterferon alfa-2b, as
well as the company's investigational oncology compounds including SCH 727965.
-- TEMODAR(R): Twenty-eight abstracts will be presented, including 10
poster discussions and eight oral presentations.
-- CAELYX(R): Eleven abstracts will be presented, including two poster
discussions and two oral presentations.
-- INTRON(R) A and peginterferon alfa-2b: Data will be featured in more
than 10 abstracts, including five poster discussions and five oral
presentations.
Please see important full U.S. Prescribing Information, and the Medication
Guides for INTRON(R) A and peginterferon alfa-2b at www.schering-plough.com.
Schering-Plough Corp. has exclusive ex-U.S. marketing rights to CAELYX(R),
except in Japan and Israel, through a distribution agreement with ALZA, a
wholly owned subsidiary of Johnson & Johnson, New Brunswick, N.J., USA. The
product is marketed in the United States under the tradename DOXIL(R) by Ortho
Biotech Products, L.P. Full EU Prescribing Information may be accessed at
www.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf.
About Schering-Plough
Schering-Plough is an innovation-driven, science-centered global health
care company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and improve
lives around the world. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. Schering-Plough's vision is to "Earn Trust, Every Day" with
the doctors, patients, customers and other stakeholders served by its
colleagues around the world. The company is based in Kenilworth, N.J., and
its Web site is www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release
includes certain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
relating to the potential market and the clinical development of its oncology
portfolio. Forward-looking statements relate to expectations or forecasts of
future events. Schering-Plough does not assume the obligation to update any
forward-looking statement. Many factors could cause actual results to differ
materially from Schering-Plough's forward-looking statements, including market
forces, economic factors, product availability, patent and other intellectual
property protection, current and future branded, generic or over-the-counter
competition, the regulatory process, and any developments following regulatory
approval, among other uncertainties. For further details about these and
other factors that may impact the forward-looking statements, see
Schering-Plough's Securities and Exchange Commission filings, including Part
I, Item 1A, "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.
SOURCE Schering-Plough Corporation
